




PHARMACEUTICAL 2018

Skye Bioscience Inc.
Rank 333 of 342





PHARMACEUTICAL 2018

Skype Bioscience Inc.
Rank 333 of 342

The relative strengths and weaknesses of Skype Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skype Bioscience Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Skype Bioscience Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 308% points.

The company's Economic Capital Ratio, given in the ranking table, is -467%, being 513% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	556
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	806
Liabilities, Non-Current	551
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-559
Other Liabilities	0
Other Net Income	206
Other Revenues	0
Property and Equipment	1.4
Research and Development	311
Selling, General and Administrative Expense	3,548

Output Variable	Value in 1000 USD
Assets	557
Liabilities	1,357
Expenses	3,301
Revenues	0
Stockholders Equity	-800
Net Income	-3,094
Comprehensive Net Income	-3,094
Economic Capital Ratio	-467%